Anthracycline, Trastuzumab, and Cardiovascular Toxicity

T. R. Cochran, V. I. Franco, R. Scully, Steven E Lipshultz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

Original languageEnglish (US)
Title of host publicationCardiovascular Toxicology
PublisherElsevier Inc.
Pages432-446
Number of pages15
Volume13-15
ISBN (Electronic)9780081006122
ISBN (Print)9780081006016
DOIs
StatePublished - Dec 15 2017
Externally publishedYes

Fingerprint

Anthracyclines
Heart Neoplasms
Radiation Effects
Therapeutics
Carcinogenesis
Morbidity
Drug Therapy
Mortality
Trastuzumab
Pharmaceutical Preparations
Neoplasms
Cardiotoxicity

Keywords

  • Adverse effects
  • Antineoplastic antibiotics
  • Cancer survivorship
  • Cardiac biomarkers
  • Cardiomyopathy
  • Cardioprotection
  • Cardiotoxicity
  • Congestive heart failure
  • Dexrazoxane
  • Doxorubicin
  • Echocardiography
  • Epirubicin
  • Idarubicin
  • Late effects
  • Mitoxantrone
  • Monitoring
  • Neuregulin
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cochran, T. R., Franco, V. I., Scully, R., & Lipshultz, S. E. (2017). Anthracycline, Trastuzumab, and Cardiovascular Toxicity. In Cardiovascular Toxicology (Vol. 13-15, pp. 432-446). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801238-3.95641-1

Anthracycline, Trastuzumab, and Cardiovascular Toxicity. / Cochran, T. R.; Franco, V. I.; Scully, R.; Lipshultz, Steven E.

Cardiovascular Toxicology. Vol. 13-15 Elsevier Inc., 2017. p. 432-446.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cochran, TR, Franco, VI, Scully, R & Lipshultz, SE 2017, Anthracycline, Trastuzumab, and Cardiovascular Toxicity. in Cardiovascular Toxicology. vol. 13-15, Elsevier Inc., pp. 432-446. https://doi.org/10.1016/B978-0-12-801238-3.95641-1
Cochran TR, Franco VI, Scully R, Lipshultz SE. Anthracycline, Trastuzumab, and Cardiovascular Toxicity. In Cardiovascular Toxicology. Vol. 13-15. Elsevier Inc. 2017. p. 432-446 https://doi.org/10.1016/B978-0-12-801238-3.95641-1
Cochran, T. R. ; Franco, V. I. ; Scully, R. ; Lipshultz, Steven E. / Anthracycline, Trastuzumab, and Cardiovascular Toxicity. Cardiovascular Toxicology. Vol. 13-15 Elsevier Inc., 2017. pp. 432-446
@inbook{5ce58b647bcf4154be218d5b70d1de76,
title = "Anthracycline, Trastuzumab, and Cardiovascular Toxicity",
abstract = "In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.",
keywords = "Adverse effects, Antineoplastic antibiotics, Cancer survivorship, Cardiac biomarkers, Cardiomyopathy, Cardioprotection, Cardiotoxicity, Congestive heart failure, Dexrazoxane, Doxorubicin, Echocardiography, Epirubicin, Idarubicin, Late effects, Mitoxantrone, Monitoring, Neuregulin, Trastuzumab",
author = "Cochran, {T. R.} and Franco, {V. I.} and R. Scully and Lipshultz, {Steven E}",
year = "2017",
month = "12",
day = "15",
doi = "10.1016/B978-0-12-801238-3.95641-1",
language = "English (US)",
isbn = "9780081006016",
volume = "13-15",
pages = "432--446",
booktitle = "Cardiovascular Toxicology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Anthracycline, Trastuzumab, and Cardiovascular Toxicity

AU - Cochran, T. R.

AU - Franco, V. I.

AU - Scully, R.

AU - Lipshultz, Steven E

PY - 2017/12/15

Y1 - 2017/12/15

N2 - In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

AB - In cancer treatment, the pervasive late effects of radiation and chemotherapy limit their utility, especially in children, in whom treatment often leads to lifelong morbidity and excess mortality. Advances in understanding the molecular pathways related to tumorigenesis have led to the development of targeted therapies, but recurrent late effects, as in the case of trastuzumab, and unexpectedly high rates of cardiotoxicity highlight gaps in our understanding of drug pathways and the mechanisms of treatment toxicity. Here, we review the mechanisms of anthracycline activity in tumor and cardiac cells, as well as the clinical manifestations and their associated cardiotoxicity, prevention strategies, and monitoring recommendations. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

KW - Adverse effects

KW - Antineoplastic antibiotics

KW - Cancer survivorship

KW - Cardiac biomarkers

KW - Cardiomyopathy

KW - Cardioprotection

KW - Cardiotoxicity

KW - Congestive heart failure

KW - Dexrazoxane

KW - Doxorubicin

KW - Echocardiography

KW - Epirubicin

KW - Idarubicin

KW - Late effects

KW - Mitoxantrone

KW - Monitoring

KW - Neuregulin

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85043339024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043339024&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801238-3.95641-1

DO - 10.1016/B978-0-12-801238-3.95641-1

M3 - Chapter

AN - SCOPUS:85043339024

SN - 9780081006016

VL - 13-15

SP - 432

EP - 446

BT - Cardiovascular Toxicology

PB - Elsevier Inc.

ER -